Filing Flows › Atara Biotherapeutics (ATRA) › Q1 2026 › vs Q1 2025
Atara Biotherapeutics (ATRA) Q1 2026 vs Q1 2025 (year over year)
Atara Biotherapeutics's revenue fell $97.6M (-99%) from $98.1M in Q1 2025 to $516K in Q1 2026.
Atara Biotherapeutics, Q1 2026: revenue $516K (-100% year over year), operating margin -652.9%, net loss $4.1M, operating cash flow −$3.1M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $516K | $98.1M | −$97.6M | -99% |
| Net loss | $4.1M | −$38.0M | $42.2M | — |
| Costs & expenses | $4.7M | $98.1M | −$93.5M | -95% |
| Operating costs | $3.9M | $59.3M | −$55.5M | -93% |
| Interest & other, net | $776K | $792K | −$16K | -2% |
| Research & development | $164K | $27.4M | −$27.3M | -99% |
| General & admin | $3.6M | $11.5M | −$7.9M | -69% |
| Other operating costs | $124K | $20.4M | −$20.3M | -99% |
| Operating cash sources | $4.1M | −$38.0M | $42.2M | — |
| Depreciation & amortization | $29K | $1.8M | −$1.8M | -98% |
| Share-based compensation | $749K | $4.2M | −$3.5M | -82% |
| Working capital & other | $294K | −$72.2M | $72.4M | — |
| Cash used in operations | $3.1M | $28.1M | −$25.1M | -89% |
| Net loss absorbed | $4.1M | −$38.0M | $42.2M | — |
Questions
How much did Atara Biotherapeutics's revenue grow year over year in Q1 2026?
Atara Biotherapeutics's revenue fell $97.6M (-99%) from $98.1M in Q1 2025 to $516K in Q1 2026.